MCID: LYM019
MIFTS: 41

Lymphosarcoma

Categories: Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma 19 75 53 75
Lymphoma, Diffuse 71
Lymphoma 71

Classifications:



External Ids:

UMLS 71 C0024299 C3714542

Summaries for Lymphosarcoma

MalaCards based summary: Lymphosarcoma, also known as lymphoma, diffuse, is related to lymphoma, non-hodgkin, familial and reticulosarcoma. An important gene associated with Lymphosarcoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Direct p53 effectors and Interleukin-4 and Interleukin-13 signaling. The drugs Ferrous succinate and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and myeloid.

Wikipedia: 75 Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood... more...

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 31.3 TNFRSF8 IGH BCL6 BCL2
2 reticulosarcoma 29.9 TNFRSF8 IGH BCL6 BCL2
3 follicular lymphoma 29.8 IGH BCL6 BCL2
4 lymphoma, hodgkin, classic 29.8 TNFRSF8 BCL6 BCL2
5 leukemia, acute lymphoblastic 29.8 IGH BCL6 BCL2
6 lymphoma 29.7 TNFRSF8 BCL6 BCL2
7 plasmacytoma 29.7 IGH BCL2
8 leukemia, chronic lymphocytic 29.6 TNFRSF8 IGH BCL6 BCL2
9 diffuse large b-cell lymphoma 29.5 TNFRSF8 BCL6 BCL2
10 lymphoblastic lymphoma 29.4 TNFRSF8 BCL6 BCL2
11 lymphoproliferative syndrome 29.4 TNFRSF8 BCL6 BCL2
12 burkitt lymphoma 29.4 TNFRSF8 DNMT1 BCL6 BCL2
13 gastric lymphoma 29.4 TNFRSF8 BCL6 BCL2
14 small intestine lymphoma 29.3 TNFRSF8 BCL6
15 mycosis fungoides 29.3 TNFRSF8 BCL2
16 sezary's disease 29.3 TNFRSF8 BCL6 BCL2
17 richter's syndrome 29.2 TNFRSF8 BCL6 BCL2
18 myeloma, multiple 29.2 TNFRSF8 BCL6 BCL2
19 adult t-cell leukemia/lymphoma 29.2 TNFRSF8 BCL2
20 leukemia, acute myeloid 29.2 TNFRSF8 DNMT1 BCL6 BCL2
21 anaplastic large cell lymphoma 29.0 TNFRSF8 BCL2
22 peripheral t-cell lymphoma 29.0 TNFRSF8 BCL6 BCL2
23 hematologic cancer 28.9 TNFRSF8 DNMT1 BCL2
24 b-cell lymphoma 28.8 TNFRSF8 IGH BCL6 BCL2
25 mantle cell lymphoma 28.5 TNFRSF8 IGH BCL6 BCL2
26 reticulum cell sarcoma 10.5
27 interdigitating dendritic cell sarcoma 10.5
28 sarcoma 10.4
29 leukemia 10.4
30 acute leukemia 10.4
31 myeloid leukemia 10.2
32 sarcoidosis 1 10.2
33 leukemia, chronic lymphocytic 2 10.1
34 hemolytic anemia 10.1
35 peritonitis 10.1
36 hypereosinophilic syndrome 10.1
37 posttransplant acute limbic encephalitis 10.1
38 intussusception 10.1
39 leukemia, chronic myeloid 10.1
40 gastric cancer 10.1
41 fungal infectious disease 10.1
42 hypoglycemia 10.1
43 splenomegaly 10.1
44 intravascular large b-cell lymphoma 10.0 BCL6 BCL2
45 down syndrome 10.0
46 deficiency anemia 10.0
47 uveitis 10.0
48 lymphopenia 10.0
49 heart lymphoma 10.0 BCL6 BCL2
50 ovarian lymphoma 10.0 BCL6 BCL2

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma

Symptoms & Phenotypes for Lymphosarcoma

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 890)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous succinate Approved Phase 4 10030-90-7
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
Rasburicase Approved, Investigational Phase 4 134774-45-1
5
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
6
Infliximab Approved Phase 4 170277-31-3
7
Golimumab Approved Phase 4 476181-74-5
8
Teniposide Approved Phase 4 29767-20-2 34698 452548
9
Amifostine Approved, Investigational Phase 4 20537-88-6 2141
10
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
11
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
12
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-56-5 148211 6337614
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
15
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
16
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
17
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
18
Treosulfan Approved, Investigational Phase 4 299-75-2 9296
19
Idarubicin Approved Phase 4 58957-92-9 42890
20
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
21
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
22
Prilocaine Approved Phase 4 721-50-6 4906
23
Simvastatin Approved Phase 4 79902-63-9 54454
24
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
25
Methoxsalen Approved Phase 4 298-81-7 4114
26
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
27
Zidovudine Approved Phase 4 30516-87-1 35370
28
Ribavirin Approved Phase 4 36791-04-5 37542
29
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
30
Ledipasvir Approved Phase 4 1256388-51-8 67505836
31
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
33
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
34
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731
35
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
36
Rivoceranib Investigational Phase 4 811803-05-1 11315474
37
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
38
Fotemustine Investigational Phase 4 92118-27-9 104799
39
Ethylene Phase 4 74-85-1 6325
40 Neurotransmitter Agents Phase 4
41 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
42 Calciferol Phase 4
43 Cyclooxygenase Inhibitors Phase 4
44 Endothelial Growth Factors Phase 4
45 Antiprotozoal Agents Phase 4
46 Antiparasitic Agents Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4
48 Tumor Necrosis Factor Inhibitors Phase 4
49 Dopamine Agents Phase 4
50 Neurokinin-1 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 7922)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
3 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
4 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Unknown status NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
5 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
6 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma Unknown status NCT04040491 Phase 4 PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine
7 Single-arm, Multi-center Clinical Study of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory Natural Killer/T Cell Lymphoma Unknown status NCT04038411 Phase 4 PD-1 Antibody, chidamide, lenalidomide and etoposide
8 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
9 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
10 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
11 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
12 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
13 A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Unknown status NCT04490590 Phase 4 Chidamide+ Etoposide
14 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
15 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
16 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
17 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Unknown status NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
18 Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma Unknown status NCT04083079 Phase 4 PEG-rhG-CSF;rhG-CSF
19 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
20 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Unknown status NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
21 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Unknown status NCT02992834 Phase 4
22 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
23 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Unknown status NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
24 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
25 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
26 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
27 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
28 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
29 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
30 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
31 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
32 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
33 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
34 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
35 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
36 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Unknown status NCT03920813 Phase 4 Mercaptopurine
37 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
38 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
39 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
40 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
41 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
42 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
43 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
44 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
45 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
46 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
47 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
48 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
49 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
50 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

Organs/tissues related to Lymphosarcoma:

MalaCards : T Cells, Bone Marrow, Myeloid, Nk Cells, Bone, Lung, Breast

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 3802)
# Title Authors PMID Year
1
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 53 62
12426140 2002
2
[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. 53 62
11494447 2001
3
Dendritic Cell-Derived Artificial Microvesicles Inhibit RLS40 Lymphosarcoma Growth in Mice via Stimulation of Th1/Th17 Immune Response. 62
36432733 2022
4
Single Shot vs. Cocktail: A Comparison of Mono- and Combinative Application of miRNA-Targeted Mesyl Oligonucleotides for Efficient Antitumor Therapy. 62
36139555 2022
5
Characterization of miRNAs in Milk Small Extracellular Vesicles from Enzootic Bovine Leukosis Cattle. 62
36142686 2022
6
Rapid Progression of Large B-cell Lymphoma in Behçet's Disease on Immunosuppressive Therapy: A Case Report with Literature Review. 62
36120251 2022
7
Cutaneous epitheliotropic lymphosarcoma in a captive white catfish (Ameiurus catus Linnaeus). 62
35475494 2022
8
Comparing microRNA in milk small extracellular vesicles among healthy cattle and cattle at high risk for bovine leukemia virus transmission. 62
35465986 2022
9
Investigation of the target genes of BLV miRNAs and the expression levels of miR-B4-3p and miR-B2-5p in cattle infected with Bovine Leukemia Virus. 62
35919847 2022
10
Identification of Potential mRNA Biomarkers in Milk Small Extracellular Vesicles of Enzootic Bovine Leukosis Cattle. 62
35632763 2022
11
Synthesis and biological evaluation of new derivatives of grossheimin. 62
35151803 2022
12
Syntheses Based on 3,4α-Epoxy-1,5,7α,6β(H)-guai-10(14),11(13)-dien-6,12-olide. 62
35335225 2022
13
[Activity of the Russian antitumor compound chlonisol in models of eyelid tumors (experimental study)]. 62
36004585 2022
14
In Vivo Antitumoral Effects of Linseed Oil and Its Combination With Doxorubicin. 62
35800445 2022
15
Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020. 62
33733992 2021
16
Study on the anti-hepatocarcinoma effect and molecular mechanism of Prunella vulgaris total flavonoids. 62
33675913 2021
17
Proteomic profiling of milk small extracellular vesicles from bovine leukemia virus-infected cattle. 62
33536533 2021
18
Data on proteomic analysis of milk extracellular vesicles from bovine leukemia virus-infected cattle. 62
33294510 2020
19
Antitumour Activity of the Ribonuclease Binase from Bacillus pumilus in the RLS40 Tumour Model Is Associated with the Reorganisation of the miRNA Network and Reversion of Cancer-Related Cascades to Normal Functioning. 62
33147876 2020
20
CpG Site-Specific Regulation of Metallothionein-1 Gene Expression. 62
32824906 2020
21
Impact of bovine leukemia virus infection on beef cow longevity. 62
32593082 2020
22
Phylogenetic Analysis of South African Bovine Leukaemia Virus (BLV) Isolates. 62
32824449 2020
23
Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. 62
32146418 2020
24
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. 62
32014922 2020
25
Whole genome sequencing analysis of high confidence variants of B-cell lymphoma in Canis familiaris. 62
32857815 2020
26
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis. 62
31759344 2019
27
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. 62
30993718 2019
28
Detection and Identification of Enzootic Bovine Leukosis (EBL) in Calves in Iran. 62
31592598 2019
29
Prevalence and clinical significance of koala retrovirus in two South Australian koala (Phascolarctos cinereus) populations. 62
31162024 2019
30
Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation. 62
30909988 2019
31
Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? 62
30411396 2019
32
Neurolymphomatosis caused by T-cell lymphosarcoma in a cat: imaging description and treatment review. 62
30828460 2019
33
Long-term cadmium exposure enhances metallothionein-1 induction after subsequent exposure to high concentrations of cadmium in P1798 mouse lymphosarcoma cells. 62
30944283 2019
34
Isolation, Purification, Characterisation and Application of L-ASNase: A Review. 62
30318009 2019
35
Characterisation of infection associated microRNA and protein cargo in extracellular vesicles of Theileria annulata infected leukocytes. 62
30370674 2019
36
Lymphocyte proliferation and apoptosis of lymphocyte subpopulations in bovine leukemia virus-infected dairy cows with high and low proviral load. 62
30502911 2018
37
A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography. 62
30155702 2018
38
Can Bovine Leukemia Virus Be Related to Human Breast Cancer? A Review of the Evidence. 62
29777406 2018
39
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 62
29872609 2018
40
Molecular epidemiology and characterization of bovine leukemia virus in domestic yaks (Bos grunniens) on the Qinghai-Tibet Plateau, China. 62
29224130 2018
41
Genome-wide scan for commons SNPs affecting bovine leukemia virus infection level in dairy cattle. 62
29439661 2018
42
Bovine leukaemia virus genotypes 5 and 6 are circulating in cattle from the state of São Paulo, Brazil. 62
29120299 2017
43
Renal neoplasia in horses - a retrospective study. 62
28933507 2017
44
BOLA-DRB3 gene polymorphisms influence bovine leukaemia virus infection levels in Holstein and Holstein × Jersey crossbreed dairy cattle. 62
28568505 2017
45
Acute Lameness in a Roller Pigeon ( Columba livia ) with Multicentric Lymphosarcoma. 62
28665728 2017
46
Cytomegalovirus retinitis in a patient with secondary acute lymphosarcoma leukemia undergoing allogeneic hematopoietic stem-cell transplantation: A rare case report: a care-compliant article. 62
28489788 2017
47
miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells. 62
28126663 2017
48
A novel pulmonary polyomavirus in alpacas (Vicugna pacos). 62
28284622 2017
49
Therapeutic l-asparaginase: upstream, downstream and beyond. 62
26694875 2017
50
Four Cases of Spontaneous Neoplasia in the Naked Mole-Rat (Heterocephalus glaber), A Putative Cancer-Resistant Species. 62
27129918 2017

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Pathways for Lymphosarcoma

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.48 BCL6 BCL2
2 11.36 BCL6 BCL2
3 11.27 BCL6 BCL2
4 11.16 BCL6 BCL2
5
Show member pathways
10.82 TNFRSF8 BCL2
6 9.92 DNMT1 BCL2

GO Terms for Lymphosarcoma

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.92 DNMT1 BCL6

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell proliferation GO:0042100 9.56 BCL6 BCL2
2 positive regulation of B cell proliferation GO:0030890 9.46 BCL6 BCL2
3 positive regulation of apoptotic process GO:0043065 9.43 TNFRSF8 BCL6 BCL2
4 negative regulation of B cell apoptotic process GO:0002903 8.92 BCL2 BCL6

Sources for Lymphosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....